Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Farmacopia, LLC

Active
State & Local

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

Farmacopia, LLC is authorized to operate a Manufacturing Type 6 Non-volatile Solvent Extraction facility at 9060 Winnetka Ave., Northridge, California, within an existing building on a 292-foot by 242-foot lot, with no expansion or major structural modifications planned. The operation is licensed under California state law and complies with the Business and Professions Code Division 10, Chapter 2, Section 26012, focusing solely on the production of commercial cannabis products using non-volatile solvent extraction methods. The project has been granted a Class 1 Categorical Exemption under Cal. Code Regs., Title 14, §15301, affirming that the activity involves only minor alterations to an existing structure with no significant environmental impact, and all utility services are supplied by the City of Los Angeles Department of Water and Power. The Department of Cannabis Control, through its Cultivation Licensing Branch, oversees regulatory compliance, with Tia Heu listed as the primary environmental contact, and the facility is subject to inspection and enforcement at its Northridge location. No formal contract value, pricing structure, payment terms, invoicing mechanisms, or federal procurement clauses are applicable or documented, as this is a state-level licensing action rather than a competitive federal acquisition. The process follows ministerial approval based on regulatory alignment with California’s environmental and cannabis statutes, without the use of federal standard acquisition formats, evaluation factors, or financial data typically found in government contracts. No representations regarding business size, socioeconomic status, or federal certifications were required or submitted, and the approval is predicated on compliance with state law and environmental exemption criteria rather than competitive bidding or performance-based incentives.

General Info

Farmacopia, LLC licensed to operate non-volatile solvent extraction for cannabis in Northridge, California, under state regulations with no environmental impact.

Agency

California Cannabis Control, Department of

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

CA

Set-Aside

NONE

Documents

(1)

Farmacopia LLC Cannabis License Environmental Exemption Notice

PDFenvironmental-exemption-notice

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyCalifornia Cannabis Control, Department of
Contacts1 person available
OfficeN/A
Organization / Agency
California Cannabis Control, Department of
Office AddressN/A
Contacts
Tia HeuEnvironmental Scientist

Full Description

Show more
The Proposed Project will operate a Manufacturing Type 6 Non-volatile Solvent Extraction license within an existing building at 9060 Winnetka Ave., Northridge, CA 91324 (APN 2782-037-016). The Project will conduct non-volatile solvent extractions to manufacture commercial cannabis products under State and local law. The Project site is one lot approximately 292 feet deep and a width of 242 feet along Winnetka Avenue. The site is developed with an existing building. Building modifications are minimal and no changes beyond existing use are proposed. Utilities such as sewer, electricity, and water will be provided by the City of Los Angeles Department of Water and Power.

Similar Contracts

Same NAICS industry code

NAICS: 325412
New
Federal
Non-Addictive Battlefield Pain Management SolutionsThe contract seeks the development of non-opioid analgesics or alternative pain relief technologies designed for military use in austere environments, with a focus on creating effective, non-addictive solutions that can be deployed in combat or field conditions where traditional pain management options are impractical or risky. The work must address the unique challenges of battlefield medicine, including limited resources, extreme climates, and the need for rapid, reliable pain control without the potential for dependency or misuse. The technology must be robust, easily transportable, and compatible with existing military medical protocols and equipment. The contract is structured as a subcontract under the Defense Health Agency, part of the Department of Defense, and is governed by the NAICS code 325412 for pharmaceutical preparation manufacturing. Proposals must be submitted by October 30, 2026, and performance will center in Frederick, with no specific city, state, or zip provided beyond that location. There is no set-aside classification applied to this opportunity, and while no point of contact is listed, interested parties can access additional details through the provided SAM.gov link. The initiative reflects a strategic priority to reduce reliance on opioid-based treatments in military healthcare and advance innovations that enhance soldier readiness and long-term health outcomes.
Defense Health Agency

POSTED

1 day ago

DEADLINE

in 3 months
View Details
NAICS: 325412
New
Federal
Library of Pharmacologically Active Compounds (LOP
Solicitation # 75N98026Q00991
The National Institutes of Health, Office of the Director, Office of Acquisitions, is soliciting proposals under solicitation number 75N98026Q00991 for the Library of Pharmacologically Active Compounds (LOPAC), conducted as a commercial item acquisition under FAR Subpart 12.6. This is an unrestricted, full and open competition with no set-aside, targeting vendors capable of delivering a defined set of pharmacologically active compounds as 1000x stock solutions in 100% DMSO for use in a broad cancer cell line screening study via the PRISM platform. The contract is a Firm-Fixed-Price type, with an estimated value not to exceed the simplified acquisition threshold of $250,000, and the NAICS code 325412 applies with a small business size standard of 1,300 employees. All offerors must be actively registered in the System for Award Management with a valid Unique Entity Identifier and Taxpayer Identification Number, and must certify their business size status. Proposals must include pricing details, shipping and handling costs, delivery timeframe, F.O.B. destination, and product catalog numbers, submitted electronically to Jaddua.Johnston@nih.gov by 8:00 AM EST on August 24, 2026. Performance is required to begin on September 4, 2026, with an end date of December 3, 2026, and deliverables include cell line viability data, assay quality control metrics, univariate and multivariate feature correlation analyses, and all raw data generated from screening activities, to be submitted through the PRISM Portal approximately four months after the submission window closes. The government will provide the test compound and expects full compliance with the PRISM assay protocol using an 8-point, 3-fold dilution series in a 5-day Luminex-format assay. Packaging must meet commercial standards, with no military specifications or labeling requirements beyond shipment in 100% DMSO to NIH/NCATS at 9808 Medical Center Drive, Rockville, MD 20850. Invoices must be submitted electronically via the Invoicing Processing Platform (IPP). Evaluation will be based on price, technical capability, past performance, and delivery schedule, with award going to the offeror providing the best value to the government through a trade-off process, not necessarily the lowest price. All
National Institutes Of Health Olao

POSTED

1 day ago

DEADLINE

in 16 days
View Details
NAICS: 325412
New
Federal
Government Contracting Compliance & GSA Schedule SupportThe contract solicits the supply of biotechnology reagents through existing GSA Schedule or GWAC vehicles, requiring full compliance with the Federal Acquisition Regulation for pricing and delivery terms. All offerings must leverage pre-negotiated, FAR-compliant contractual mechanisms to ensure transparency, affordability, and efficiency in procurement by the National Institutes of Health, specifically the National Institute on Drug Abuse under the Department of Health and Human Services. The NAICS code 325412 confirms the primary focus on pharmaceutical and biological product manufacturing, indicating the need for high-purity, research-grade reagents suitable for scientific and clinical applications. Responses must be submitted by August 13, 2026, and the contract is structured as a subcontract, implying the awardee will fulfill obligations under a prime contract holder rather than directly with the government. Performance is expected to align with federal supply chain standards, though no specific place of performance or set-aside criteria are provided. Compliance with GSA Schedule or GWAC terms is mandatory, ensuring that pricing remains consistent with established federal rates and that delivery timelines meet agency operational needs. The solicitation underscores the importance of proven regulatory adherence and reliable supply chain execution to support critical biomedical research activities.
National Institutes Of Health Nida

POSTED

2 days ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
Federal
Specialty Biotech Reagent Manufacturing (dCODE Dextramer®)The contract involves the manufacture of specialized immunology reagents based on dextramer technology, specifically customizable HLA-peptide complexes equipped with fluorescent barcoding, intended for use in research and clinical applications. These reagents are designed to enable precise detection and analysis of antigen-specific T cells, supporting advancements in immunological studies and potential therapeutic development. The production must meet stringent quality and consistency standards to ensure reliability across diverse experimental and diagnostic settings, with an emphasis on scalability and customization to accommodate varying peptide and HLA combinations. This is a subcontract under the National Institutes of Health, specifically the National Institute on Drug Abuse, part of the Department of Health and Human Services, with the NAICS code 325412 indicating biological product manufacturing. The opportunity was posted on August 6, 2026, and responses are due by August 13, 2026, with no set-aside classification specified. The place of performance and other location details are not provided, indicating flexibility in where the manufacturing may occur, though all work must comply with the technical and regulatory requirements for clinical-grade reagents. The focus is squarely on advanced biotech manufacturing capabilities, emphasizing precision, reproducibility, and compliance with industry best practices for immune monitoring tools.
National Institutes Of Health Nida

POSTED

2 days ago

DEADLINE

in 5 days
View Details